BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet 2021;397:2195-211. [PMID: 34090606 DOI: 10.1016/S0140-6736(20)32542-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 So M, Walti L. Challenges of Antimicrobial Resistance and Stewardship in Solid Organ Transplant Patients. Curr Infect Dis Rep. [DOI: 10.1007/s11908-022-00778-1] [Reference Citation Analysis]
2 Moore JE, Millar BC. "Be afraid - be very afraid": Passive air drying of nebulizer parts in cystic fibrosis (CF) - Occult microbiological risks of contamination with Pseudomonas aeruginosa from calyptrate flies (Musca domestica &Calliphora vomitoria). J Hosp Infect 2022:S0195-6701(22)00069-X. [PMID: 35247495 DOI: 10.1016/j.jhin.2022.02.018] [Reference Citation Analysis]
3 Picci G, Marchesan S, Caltagirone C. Ion Channels and Transporters as Therapeutic Agents: From Biomolecules to Supramolecular Medicinal Chemistry. Biomedicines 2022;10:885. [DOI: 10.3390/biomedicines10040885] [Reference Citation Analysis]
4 Migliorisi G, Collura M, Ficili F, Pensabene T, Bongiorno D, Collura A, Di Bernardo F, Stefani S. Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals 2022;15:606. [DOI: 10.3390/ph15050606] [Reference Citation Analysis]
5 Saluzzo F, Riberi L, Messore B, Loré NI, Esposito I, Bignamini E, De Rose V. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells 2022;11:1243. [DOI: 10.3390/cells11071243] [Reference Citation Analysis]
6 Cabrini G, Rimessi A, Borgatti M, Pinton P, Gambari R. Overview of CF lung pathophysiology. Curr Opin Pharmacol 2022;64:102214. [PMID: 35453033 DOI: 10.1016/j.coph.2022.102214] [Reference Citation Analysis]
7 Nayir Buyuksahin H, Emiralioglu N, Ozsezen B, Ademhan Tural D, Sunman B, Guzelkas I, Tezel B, Dayangaç Erden D, Yalçın E, Dogru D, Ozcelik U, Kiper N. Cystic fibrosis newborn screening: Five-year experience from a tertiary care center. Pediatr Pulmonol 2021. [PMID: 34842364 DOI: 10.1002/ppul.25778] [Reference Citation Analysis]
8 Behroozian S, Sampedro I, Dhodary B, Her S, Yu Q, Stanton BA, Hill JE. Pseudomonas aeruginosa PAO1 Is Attracted to Bovine Bile in a Novel, Cystic Fibrosis-Derived Bronchial Epithelial Cell Model. Microorganisms 2022;10:716. [DOI: 10.3390/microorganisms10040716] [Reference Citation Analysis]
9 Strandvik B. Nutrition in Cystic Fibrosis—Some Notes on the Fat Recommendations. Nutrients 2022;14:853. [DOI: 10.3390/nu14040853] [Reference Citation Analysis]
10 Brooks IR, Garrone CM, Kerins C, Kiar CS, Syntaka S, Xu JZ, Spagnoli FM, Watt FM. Functional genomics and the future of iPSCs in disease modeling. Stem Cell Reports 2022;17:1033-47. [PMID: 35487213 DOI: 10.1016/j.stemcr.2022.03.019] [Reference Citation Analysis]
11 Borgo C, D'Amore C, Capurro V, Tomati V, Sondo E, Cresta F, Castellani C, Pedemonte N, Salvi M. Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants. Cell Mol Life Sci 2022;79:192. [PMID: 35292885 DOI: 10.1007/s00018-022-04215-3] [Reference Citation Analysis]
12 Cabral B, Terlizzi V, Laselva O, Conte Filho C, Mota F. Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers. JCM 2022;11:1283. [DOI: 10.3390/jcm11051283] [Reference Citation Analysis]
13 Mozzillo E, Maltoni G, Chiavaroli V, Dovc K, Marigliano M. Editorial: New Insights in Diagnosing and Treatment of Glucose Disorders and Obesity in Children and Adolescents. Front Pediatr 2021;9:786055. [PMID: 34869129 DOI: 10.3389/fped.2021.786055] [Reference Citation Analysis]
14 von Köckritz-blickwede M, Winstel V. Molecular Prerequisites for Neutrophil Extracellular Trap Formation and Evasion Mechanisms of Staphylococcus aureus. Front Immunol 2022;13:836278. [DOI: 10.3389/fimmu.2022.836278] [Reference Citation Analysis]
15 Ribeiro CMP, McElvaney NG, Cabrini G. Editorial: Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Front Pharmacol 2021;12:794854. [PMID: 34867428 DOI: 10.3389/fphar.2021.794854] [Reference Citation Analysis]
16 Lukasiak A, Zajac M. The Distribution and Role of the CFTR Protein in the Intracellular Compartments. Membranes (Basel) 2021;11:804. [PMID: 34832033 DOI: 10.3390/membranes11110804] [Reference Citation Analysis]
17 Tickner C, Holland L, Wark P, Hilton J, Morrison C, Kay-Lambkin F, Heinsch M. Mental health care needs in cystic fibrosis: A scoping review. Soc Work Health Care 2022;:1-15. [PMID: 35422201 DOI: 10.1080/00981389.2022.2060422] [Reference Citation Analysis]
18 Mergiotti M, Murabito A, Prono G, Ghigo A. CFTR Modulator Therapy for Rare CFTR Mutants. JoR 2022;2:59-76. [DOI: 10.3390/jor2020005] [Reference Citation Analysis]
19 Wang J, Sun X, Xie Y, Long Y, Chen H, He X, Zou T, Mao Z, Xia W. Identification of an Au(I) N-Heterocyclic Carbene Compound as a Bactericidal Agent Against Pseudomonas aeruginosa. Front Chem 2022;10:895159. [DOI: 10.3389/fchem.2022.895159] [Reference Citation Analysis]
20 Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. Journal of Cystic Fibrosis 2022. [DOI: 10.1016/j.jcf.2022.01.009] [Reference Citation Analysis]
21 Ghigo A, Murabito A, Sala V, Pisano AR, Bertolini S, Gianotti A, Caci E, Montresor A, Premchandar A, Pirozzi F, Ren K, Della Sala A, Mergiotti M, Richter W, de Poel E, Matthey M, Caldrer S, Cardone RA, Civiletti F, Costamagna A, Quinney NL, Butnarasu C, Visentin S, Ruggiero MR, Baroni S, Crich SG, Ramel D, Laffargue M, Tocchetti CG, Levi R, Conti M, Lu XY, Melotti P, Sorio C, De Rose V, Facchinetti F, Fanelli V, Wenzel D, Fleischmann BK, Mall MA, Beekman J, Laudanna C, Gentzsch M, Lukacs GL, Pedemonte N, Hirsch E. A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases. Sci Transl Med 2022;14:eabl6328. [PMID: 35353541 DOI: 10.1126/scitranslmed.abl6328] [Reference Citation Analysis]
22 Mercier J, Calmel C, Mésinèle J, Sutanto E, Merabtene F, Longchampt E, Sage E, Kicic A, Boëlle P, Corvol H, Ruffin M, Guillot L. SLC6A14 Impacts Cystic Fibrosis Lung Disease Severity via mTOR and Epithelial Repair Modulation. Front Mol Biosci 2022;9:850261. [DOI: 10.3389/fmolb.2022.850261] [Reference Citation Analysis]
23 Stanjek-cichoracka A, Łaszewska A, Zawadzki F, Kobylska A, Urlik M, Stącel T, Ochman M. Diagnostics of the Epstein-Barr Virus Before and After Lung Transplantation in a Patient With Developing Posttransplant Lymphoproliferative Disease: A Case Report. Transplantation Proceedings 2022. [DOI: 10.1016/j.transproceed.2022.02.028] [Reference Citation Analysis]
24 Reeves SR. Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment. Eur Respir J 2021;58:2102735. [PMID: 34857588 DOI: 10.1183/13993003.02735-2021] [Reference Citation Analysis]
25 Crisan CV, Goldberg JB. Antibacterial contact-dependent proteins secreted by Gram-negative cystic fibrosis respiratory pathogens. Trends Microbiol 2022:S0966-842X(22)00085-3. [PMID: 35487848 DOI: 10.1016/j.tim.2022.03.009] [Reference Citation Analysis]
26 Deng Z, Zhao Y, Ma Z, Zhang M, Wang H, Yi Z, Tuo B, Li T, Liu X. Pathophysiological role of ion channels and transporters in gastrointestinal mucosal diseases. Cell Mol Life Sci 2021;78:8109-25. [PMID: 34778915 DOI: 10.1007/s00018-021-04011-5] [Reference Citation Analysis]
27 Gorrieri G, Zara F, Scudieri P. SLC26A9 as a Potential Modifier and Therapeutic Target in Cystic Fibrosis Lung Disease. Biomolecules 2022;12:202. [DOI: 10.3390/biom12020202] [Reference Citation Analysis]
28 Tosco A, Castaldo A, Colombo C, Claut L, Carnovale V, Iacotucci P, Lucarelli M, Cimino G, Fabrizzi B, Caporelli N, Majo F, Ciciriello F, Padoan R, Poli P, Taccetti G, Centrone C, Casciaro R, Castellani C, Salvatore D, Colangelo C, Bonomi P, Castaldo G, Terlizzi V. Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. J Cyst Fibros 2022:S1569-1993(22)00109-6. [PMID: 35523714 DOI: 10.1016/j.jcf.2022.04.020] [Reference Citation Analysis]
29 Flores-Vega VR, Vargas-Roldán SY, Lezana-Fernández JL, Lascurain R, Santos-Preciado JI, Rosales-Reyes R. Bacterial Subversion of Autophagy in Cystic Fibrosis. Front Cell Infect Microbiol 2021;11:760922. [PMID: 34692569 DOI: 10.3389/fcimb.2021.760922] [Reference Citation Analysis]
30 Haq I, Almulhem M, Soars S, Poulton D, Brodlie M. Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis. PGPM 2022;Volume 15:91-104. [DOI: 10.2147/pgpm.s245603] [Reference Citation Analysis]
31 Costa E, Girotti S, Pauro F, Leufkens HGM, Cipolli M. The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis. Orphanet J Rare Dis 2022;17:188. [PMID: 35525974 DOI: 10.1186/s13023-022-02350-5] [Reference Citation Analysis]
32 Scott J, Jones AM, Piper Hanley K, Athwal VS. Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Aliment Pharmacol Ther 2022. [PMID: 35048397 DOI: 10.1111/apt.16749] [Reference Citation Analysis]